Insulin lispro lowers postprandial glucose in prepubertal children with diabetes.

OBJECTIVE: This study compared the glucose-lowering effect of insulin lispro, given before or after meals, with regular human insulin given before meals in prepubertal children with diabetes. RESEARCH DESIGN AND METHODS: A 3-way crossover, open-label study involving 61 prepubertal children (ages 2.9-11.4 years) with type 1 diabetes. The children were randomly assigned to receive regular human insulin 30 to 45 minutes before meals, insulin lispro within 15 minutes before or immediately after meals, combined with basal insulin. Each treatment lasted 3 months. Hemoglobin A(1c) levels and home glucose monitoring profiles were measured at the end of each treatment period. RESULTS: Treatment with insulin lispro before breakfast resulted in lower 2-hour postprandial glucose values than regular human insulin (11.7 +/- 4.4 mmol/L vs 15.0 +/- 5.4 mmol/L). Similarly, insulin lispro given before dinner resulted in lower blood glucose values 2 hours postprandially (8.8 +/- 5.0 mmol/L vs 10.8 +/- 5.4 mmol/L) than regular human insulin. When insulin lispro was administered after meals, the 2-hour glucose levels were between those seen with either insulin lispro or regular human insulin given before meals. The number and types of adverse events, the rates of hypoglycemia, and the HbA(1c) levels did not differ among the 3 therapies. CONCLUSIONS: In prepubertal children, insulin lispro given before meals is safe and significantly lowers postprandial glucose levels after breakfast and dinner compared with regular human insulin, and insulin lispro given after the meal provides similar benefits as regular human insulin before the meal.

Lipodystrophy in patients with juvenile dermatomyositis--evaluation of clinical and metabolic abnormalities.

OBJECTIVE: Lipodystrophy and associated metabolic abnormalities are being increasingly recognized as complications of juvenile dermatomyositis (JDM). We investigated the prevalence of lipodystrophy and the extent of metabolic abnormalities related to lipoatrophic diabetes mellitus in patients with JDM. METHODS: Twenty patients with JDM were evaluated for evidence of lipodystrophy and associated lipoatrophic diabetes mellitus. All patients underwent clinical assessment, laboratory investigations, and metabolic studies (oral glucose tolerance test, lipid studies, insulin antibodies). RESULTS: We found clinical evidence of lipodystrophy and lipoatrophic diabetes mellitus in 4 of 20 patients with JDM and metabolic abnormalities known to be associated with lipodystrophy in another 8 patients. The 20 patients with JDM were categorized as follows: Group 1 (Patients 1-4) consisted of patients with lipodystrophy and either diabetes mellitus (2 patients) or impaired glucose tolerance (2 patients); Group 2 (Patients 5-12): no lipodystrophy but abnormal glucose and/or lipid studies; Group 3 (Patients 13-20): no lipodystrophy and no abnormalities of glucose and lipid studies. CONCLUSION: We found 25% of patients with JDM have lipodystrophy, and 50% present with hypertriglyceridemia and insulin resistance. Screening for metabolic abnormalities in JDM should be included in routine followup because of the effect of lipodystrophy on longterm prognosis.

Growth and growth factors in premature infants receiving dexamethasone for bronchopulmonary dysplasia.

Physical growth and the serum growth factors, insulin growth factor 1 (IGF1) and its binding protein (IGFBP3) were measured weekly during dexamethasone treatment and for 3 weeks after stopping therapy in 10 ventilated babies [median (range) birth weight 860 g (640-1210); median (range) gestational age 26 weeks (24-29)] with bronchopulmonary dysplasia (BPD). The mean (+/- SE) rates of change of all physical measures except crown-rump length (CRL) increased significantly after stopping dexamethasone: weight gain 13.2 (+/- 1.5) on versus 1.0 (+/- 1.9) g/day off treatment; occipital-frontal circumference 0.7 (+/- 0.1) cm/week; CRL 0.5 (+/- 0.1) versus 0.7 (+/- 0.1) (TBL) 0.7 (+/- 0.1) versus 1.1 (+/- 0.1) cm/week; CRL 0.5 (+/- 0.1) versus 0.7 (+/- 0.1) cm/week, and knee-ankle length (KAL) 0.13 (+/- 0.02) versus 0.36 (+/- 0.04) cm/week. Mean serum IGF-1 (1.57 +/- 0.13 versus 3.56 +/- 0.41 nmol/L) and IGFBP3 (0.94 +/- 0.03 versus 1.12 +/- 0.05 mg/L) levels also increased off treatment. The weekly dose of dexamethasone (mg/kg) was significantly negatively correlated with all physical growth measures (P < 0.01), but showed no correlation with growth factors. Protein intake (g/kg/day) was significantly correlated (P < 0.01) with weight gain (r = 0.28), changes (TBL) (r = 0.32), serum IGF1 levels (r = 0.60), and IGFBP3 levels (r = 0.37). All aspects of physical growth are compromised during dexamethasone treatment for BPD. Poor growth during steroid treatment is associated with lower IGF1 and IGFBP3 levels. Further study is needed to examine the effect of varying dexamethasone dosage regimes and nutritional intake on the growth process in BPD.

The measurement of knee-heel length in newborn infants using a simple vernier calipers.

OBJECTIVE: To assess the usefulness of a simple vernier calipers for measuring knee-heel length in neonates. SUBJECTS AND METHODS: Using a simple vernier calipers, knee-heel length was measured five times by 2 observers in 50 babies (29M, 21F; mean birthweight 1597 g; median gestational age at birth 29 weeks) at a median postnatal age of 11 days. A subgroup of 20 babies had knee-heel length measured similarly at weekly intervals for 3 weeks. Corrected gestational age and weight were simultaneously recorded. One observer was experienced in using the vernier calipers. The precision of the calipers was established using 4 steel gauge blocks of varying length (7.62-10.17 cm). RESULTS: The calipers were very precise when measuring steel gauge blocks. In babies, there was a downward trend across the first 2 measurements for both observers, the measurements stabilizing over the last three. Using the final three measurements per baby (n = 50), the experienced observer had a mean standard deviation of 0.023 cm and mean coefficient of variation 0.23% when measuring an average knee-heel length of 9.99 cm. The inexperienced observer had a mean standard deviation of 0.057 cm and a mean coefficient of variation of 0.56%, when measuring an average knee-heel length of 10.14 cm. The inter-observer reliability, measured by the intra-class correlation coefficient, was 0.99. The agreement between observers was such that one observer measured knee-heel length consistently less (0.15 cm, SD 0.18 cm) than the other. The reliability for knee-heel length velocity was lower (R = 0.85), but agreement between observers was high with an average difference of 0.016 cm/week. Knee-heel length was significantly correlated (p < 0.001) with corrected gestational age (r = 0.85) and with weight (r = 0.96). There was a weaker but significant correlation (r = 0.47, p < 0.001) between knee-heel length velocity and rate of weight gain (g/day), indicating that weight gain may not always be accompanied by an increase in linear growth. CONCLUSION: The measurement of knee-heel length by a simple vernier calipers is an accurate, reproducible and non-invasive method of assessing short-term linear growth in neonates. However, it is recommended that measurements of knee-heel length in a individual baby should be made by a single experienced observer.

Vitamin D deficiency in pregnant and breast-feeding women and their infants.

We describe the cases of five consecutive infants with symptomatic vitamin D deficiency and their mothers. Four of the infants were light skinned, all had poor sunlight exposure, and all were breast-fed or had diets low in vitamin D. All mothers had vitamin D deficiency. Regardless of race, infants with poor sunlight exposure and diets lacking in vitamin D are at risk for vitamin D deficiency. Mothers of these infants should be evaluated for vitamin D deficiency. Vitamin D supplementation of the breast-feeding mother at risk and her infant is recommended.